Clementia Pharmaceuticals Inc.
CMTA
CMTA was delisted on the 17th of April, 2019.
29 hedge funds and large institutions have $301M invested in Clementia Pharmaceuticals Inc. in 2018 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 9 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 9
12% less capital invested
Capital invested by funds: $342M → $301M (-$41.7M)
24% less funds holding
Funds holding: 38 → 29 (-9)
89% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$15.3M |
| 2 |
JP Morgan Chase
New York
|
+$2.22M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$910K |
| 4 |
BC
Birchview Capital
Burlington,
Vermont
|
+$486K |
| 5 |
Morgan Stanley
New York
|
+$329K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$5.38M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$3.03M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$1.59M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$915K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$665K |
CMTA Hedge Fund Activity: Q2 2018 in Review
29 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Clementia Pharmaceuticals Inc. (CMTA) for Q2 2018, worth a combined $301M — down 12% from $342M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of CMTA and 1 opened new positions — a net loss of 8 holders — while 9 trimmed existing stakes and 9 added.
The largest buyer was Baker Bros. Advisors, adding an estimated $15.3M. The largest seller was BlackRock, exiting entirely with an estimated $5.38M sold.
- 29 institutional investors held Clementia Pharmaceuticals Inc. (CMTA) as of Q2 2018, down from 38 in Q1 2018.
- Funds reported $301M of Clementia Pharmaceuticals Inc. stock for Q2 2018, down 12% quarter-over-quarter.
- 1 fund opened new Clementia Pharmaceuticals Inc. positions in Q2 2018 and 9 closed out, a net change of -8 holders.
- The largest Clementia Pharmaceuticals Inc. buyer in Q2 2018 was Baker Bros. Advisors, an estimated $15.3M added.
- The largest Clementia Pharmaceuticals Inc. seller in Q2 2018 was BlackRock, an estimated $5.38M sold.
Based on aggregated 13F filings for Q2 2018.